Author: Dr Dewlyn Dyall-Smith FACD, Dermatologist, 2009.
Serum sickness is a self-limited allergic reaction following exposure to foreign proteins. This is sometimes called a type III hypersensitivity reaction. The resulting immune complex of the patient's antibodies bound to the foreign protein is deposited in small blood vessels and stimulates the complement cascade and hence an inflammatory reaction. It presents with a classic triad:
Serum sickness typically followed exposure to foreign, non-human proteins, especially antivenoms and antitoxins made in horse, e.g., rattlesnake antivenom used in the USA. More recently, reactions have been reported with the increasing use of thymoglobulin and chimeric monoclonal antibody therapy (biological response agents).
Thymoglobulin (anti-thymocyte globulin) is made in rabbits. It is used particularly in the perioperative period following solid organ transplants to reduce the post-operative doses of immunosuppressive drugs. The incidence of serum sickness due to thymoglobulin in renal transplant recipients has been estimated to be between 7 and 27%. There is an increased risk of developing serum sickness to thymoglobulin if there has been a significant past exposure to rabbits or horses.
Chimeric monoclonal antibodies are a group of biologic agents that are being used with increasing frequency for many immunological disorders such as rheumatoid arthritis, psoriasis and in cancer therapies.
The typical triad of serum sickness comprises fever, rash and joint pain/swelling (arthritis or arthralgia). There is also often facial swelling and lymph node enlargement. The kidneys are commonly affected.
In classic serum sickness, immune complexes deposit in small blood vessels, activating the complement cascade and resulting in inflammation. This is recognised by typical clinical features. Blood tests may detect these immune complexes or the antibodies against the foreign protein and may reveal that complement levels (C3, C4) are reduced.
Serum sickness due to thymoglobulin can be confirmed by a blood test for antiheterologous antibodies against rabbit immunoglobulin G by enzyme- linked immunosorbent assay (ELISA).
If possible the triggering therapy should be ceased.
High dose IV corticosteroids should be given for 3 days then reducing doses of oral steroids following clinical response.
If there has been no response then plasma exchange can be used to remove the immune complexes, antibodies and protein.
Serum sickness resolves usually without longterm complications.
See the DermNet NZ bookstore
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.